A Stanford Medicine study tracking 296,000 people in Wales found vaccinated individuals were 20% less likely to develop dementia over a seven-year period.
The shingles vaccine has long been recommended for older adults as protection against a painful viral flare-up. Researchers did not set out to study dementia. The data led them there anyway.
A study published in Nature by researchers at Stanford Medicine found that people who received the shingles vaccine were approximately 20% less likely to develop dementia over a seven-year follow-up period. The finding does not establish a definitive cause-and-effect relationship, but the study’s design is unusually strong for this kind of question, and the results have drawn serious attention from public health researchers.
How the study was designed
The research took advantage of a specific health policy quirk in Wales. On September 1, 2013, the Welsh government introduced the shingles vaccine with an eligibility cutoff based on age. People born just before a certain date qualified. Those born just after did not. That hard line created two otherwise comparable groups, one vaccinated and one not, without researchers having to assign anyone to a treatment.
Out of 296,324 participants tracked over seven years, 14,465 received a shingles diagnosis. Vaccinated individuals were 37.2% less likely to develop shingles than those who went unvaccinated. Among all participants, 35,307 received a new dementia diagnosis. Vaccinated individuals were 3.5% less likely to receive that diagnosis in absolute terms, which translated to a 20% relative reduction.
Why the shingles connection to dementia matters
Shingles is caused by the varicella zoster virus, the same virus responsible for chickenpox. After a chickenpox infection resolves, the virus stays dormant in nerve tissue and can reactivate decades later as shingles. Research over the past several years has increasingly pointed to viral infections, including herpes-family viruses, as potential contributors to neurological decline.
The precise mechanism connecting shingles vaccination to lower dementia risk has not been confirmed. One possibility is that preventing shingles itself prevents neurological inflammation that might otherwise accelerate cognitive damage. Another is that the vaccine’s immune-stimulating effects offer broader protection against dementia-related processes. The Stanford team did not resolve that question, and researchers are being careful not to overstate what the data shows.
Women showed stronger protective effects
The study found a gender difference in outcomes. Women who were vaccinated showed a greater reduction in new dementia diagnoses than vaccinated men. The researchers attributed this partly to known differences in how immune systems respond to vaccines. Women generally mount stronger immune responses, which may translate to greater protection against downstream effects. Whether that gap holds in larger or more diverse populations remains to be seen.
What the current evidence can and cannot support
Dr. Courtney Kloske of the Alzheimer’s Association noted that the findings are preliminary and that further research is needed before drawing firm conclusions. Dr. David Cutler, a family medicine physician, pointed specifically to the need for randomized controlled trials to establish causation rather than association.
There is also a vaccine-type question the study leaves open. The research assessed an older live-attenuated shingles vaccine. The current CDC-recommended option, Shingrix, is a recombinant vaccine with a different mechanism and a stronger efficacy profile against shingles itself. Whether Shingrix produces the same or stronger dementia-related effects is not yet known. No head-to-head data between the two vaccines on this question currently exists.
What the CDC recommends now
The CDC recommends Shingrix for adults 50 and older and for anyone over 19 with a weakened immune system. The two-dose series costs approximately $400 but is generally covered by Medicare or private insurance. The primary, well-established reason to get vaccinated remains shingles prevention. That case is strong on its own.
If subsequent research confirms the dementia connection, the cost-effectiveness argument for broader vaccination becomes considerably stronger. Dementia care carries an enormous economic burden, and a widely available, already-recommended vaccine reducing incidence even modestly would represent a meaningful shift in how prevention is approached.
